Module | Set | Terms |
---|---|---|
I. Assessment of the potential/observed pathways and impacts of COVID-19 on service delivery and/or equitable access to quality medicines and vaccines | 1 | “COVID-19” or “SARS-CoV-2” |
2 | “healthcare” or “medicines” or “drugs” or “vaccines” or “service” | |
3 | “quality” or “access” or “cost” or “affordability” or “equity” or “coverage” or “safety” or “prescription” or “innovation” | |
4 | “Africa” | |
5 | 1 and 2 and 3 and 4 | |
II. Innovations in service delivery and/or management and supply of essential medicines and vaccines applicable to manage the risks potentially associated with the COVID-19 pandemic | 1 | “drug manufacturing” or “drug procurement” or “mobile clinics” or “telephone triage” or “user fees exemption” or “task delegation” or “risk allowance” or “online medical education” |
2 | “effectiveness” or “cost-effective” or “efficiency” or “outcomes” or “strategies” or “innovations” | |
3 | “Africa” | |
4 | 1 and 2 and 3 |